XFOR
XFOR clinical trials: X4 Pharmaceuticals, Inc
Every trial on ClinicalTrials.gov where X4 Pharmaceuticals, Inc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 13
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
XFOR on the catalyst calendar · XFOR registry changes
- Primary completion Sep 2027Sponsor estimatePhase 3NCT06056297A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who...X4 Pharmaceuticals · NeutropeniaRecruitingXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 30, 2029Sponsor estimatePhase 2NCT07902830A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in...X4 Pharmaceuticals · Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersNot yet recruitingXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2026ActualPhase 1NCT06858696A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI)...X4 Pharmaceuticals · Hepatic InsufficiencyCompletedXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2025ActualPhase 3NCT03995108Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeX4 Pharmaceuticals · WHIM SyndromeCompletedXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 27, 2024ActualPhase 1/Phase 2NCT04154488A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia DisordersX4 Pharmaceuticals · NeutropeniaCompletedXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 19, 2025ActualPhase 1NCT06914869Drug-Drug Interaction Potential of MavorixaforX4 Pharmaceuticals · Healthy ParticipantsCompletedXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 16, 2022ActualPhase 2NCT03005327A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and...X4 Pharmaceuticals · WHIM SyndromeCompletedXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 14, 2022ActualPhase 1/Phase 2NCT02667886Trial of X4P-001 in Participants With Advanced Renal Cell CarcinomaX4 Pharmaceuticals · Clear Cell Renal Cell CarcinomaCompletedXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2022ActualPhase 1NCT04274738A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express...X4 Pharmaceuticals · Waldenstrom's MacroglobulinemiaCompletedXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 8, 2018ActualPhase 1/Phase 2NCT02923531Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell CarcinomaX4 Pharmaceuticals · Clear Cell Renal Cell CarcinomaTerminatedXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 15, 2018ActualPhase 1NCT02823405X4P-001 and Pembrolizumab in Patients With Advanced MelanomaX4 Pharmaceuticals · MelanomaCompletedXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2022Sponsor estimateNo phase registeredNCT03087370A Retrospective and Prospective Natural History Study of Patients With WHIM SyndromeX4 Pharmaceuticals · WHIM SyndromeWithdrawnXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2016ActualPhase 1NCT02680782A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy VolunteersX4 Pharmaceuticals · HealthyTerminatedXFORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner